目的探讨siRNA抑制人宫颈癌基因2(HCCR-2)表达对卵巢癌肝转移能力的影响。方法HCCR-2-siRNA慢病毒表达载体及空载体对照质粒感染人卵巢癌高转移细胞HO-8910PM,建立小干扰(SI)组和空白对照(NC)组。采用Western blot检测HCCR-2蛋白表达。采用Transwell法检测癌细胞侵袭能力,卵巢癌肝转移模型裸鼠观察癌细胞转移能力。两组实验数据比较采用t检验,率的比较采用x2检验。结果SI组细胞HCCR-2蛋白的平均相对表达量为0.16±0.02,较NC组的0.86±0.05明显减少(t=-8.06,P〈0.05)。SI组的穿膜细胞数为(58±3)个,较NC组的(262±19)个明显减少(t=-37.77,P〈0.05)。SI组的肝转移癌发生率2/6,较NC组的6/6明显降低(P〈0.05);SI组成瘤数量为(1.3±0.2)个,较NC组的(9.4±0.8)个明显减少(t=-10.25,P〈0.05)。结论siRNA沉默抑制HCCR-2基因表达可降低卵巢癌细胞的侵袭和肝转移能力。
Objective To investigate the impact of human cervical cancer oncogene-2 (HCCR-2) inhibited by small interference RNA (siRNA) on the liver metastatic potential of ovarian cancer. Methods High metastatic ability human ovarian cancer cell line HO-8910PM was infected using HCCR-2-siRNA lentiviral expression vector and empty negative control vector to establish small interference (SI) group and negative control (NC) group. The expression of HCCR-2 protein in two groups was detected by Western blot assay. Transwell assay was used to define the cell invasion ability. Liver metastases model of ovarian cancer was established to detect the cell metastatic ability. The data between two groups were compared using t test, and the rates were compared using Chi-square test. Results The average relative expression of HCCR-2 protein in SI group (0.16±0.02) significantly decreased compared with that in NC group (0.86±0.05) (t=-8.06, P〈0.05). The membrane permeating cell count in SI group (58±3) was significantly less than that in NC group (262±19) (t=-37.77, P〈0.05). The incidence of liver metastases in SI group (2/6) was significantly lower than that in NC group (6/6) (P〈0.05). The number of metastases in SI group (1.3 ± 0.2) was significantly less than that in NC group (9.4 ± 0.8) (t = -10.25, P〈0.05). Conclusion Inhibition of HCCR-2 gene expression by siRNA can reduce the invasion and liver metastatic potential of ovarian cancer cells.